How do MOTS-c and humanin differ?

MOTS-c is encoded in the mitochondrial 12S rRNA region and has metabolic signaling findings in models. Humanin comes from the 16S rRNA region and has cell-survival findings. Their mechanisms do not establish therapeutic benefit.

Are there human trials of either native peptide?

A native MOTS-c Phase 2 intervention is registered, but no outcome result is cited here. The selected humanin papers measure endogenous peptide or other observations, not native-humanin treatment. CB4211, HNG and colivelin are distinct analogs or derivatives.

Do higher peptide levels imply longer human life?

No. Human biomarker associations vary by population and cannot show that administering either peptide extends lifespan or improves health.

MOTS-c vs Humanin: Evidence and Limits (2026)

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Two peptides, different evidence streams

MOTS-c is a 16-residue peptide encoded in the mitochondrial 12S rRNA region. Humanin is a 24-residue peptide encoded in the 16S rRNA region. Both have laboratory and animal effects, but endogenous concentrations, native administration and modified analogs are separate evidence types. MOTS-c discovery, PMID 25738459 · humanin cell discovery, PMID 11717357

Question	MOTS-c	Humanin
Selected human work	Endogenous exercise, sleep-apnea and diabetes observations; no cited native administration result	Endogenous circulating or tissue associations; no cited controlled native administration result
Intervention models	Mouse metabolic, physical-capacity and cachexia experiments	Cell anti-apoptotic work and animal experiments; HNG is a modified analog
Therapeutic-claim grade	Low for human benefit	Low for human benefit

MOTS-c’s 2015 mouse study reported metabolic effects. A 2021 paper measured MOTS-c around exercise in people but administered peptide to mice for physical-capacity experiments. A 2026 human physiology study did not observe an exercise-related arterio-venous difference, so the claim that it consistently rises with exercise is too broad. PMID 25738459 · PMID 33473109 · PMID 41520850

A separate 2026 C26 mouse study found partial skeletal-muscle preservation with preventive MOTS-c exposure, but no prevention of overall body or fat loss and no human treatment arm. It cannot establish a cachexia or exercise-capacity treatment in people. PMID 42266945

Native humanin reduced apoptosis in early cell models; BAX interaction was studied in cells. A mouse healthspan experiment used the stronger HNG analog, while the same research reported human endogenous-level associations. Humanin biomarkers show different age or disease relationships across populations. Neither the HNG mouse result nor human biomarker patterns prove native-humanin anti-aging efficacy. PMID 12732850 · PMID 32575074 · PMID 33131010 · PMID 39102184

NCT07505745 registers native MOTS-c administration without a cited outcome. NCT03998514 tested the separate CB4211 analog. A kidney-transplant anesthesia registry measures MOTS-c and humanin but administers neither peptide. NCT07678073

The selected sources contain no direct comparison or combination result. Endogenous nature does not establish administration safety; FDA reports no identified exposure data for compounded MOTS-c products. FDA compounding safety review

This page describes selected research rather than a longevity intervention.

MOTS-c vs Humanin

MOTS-c

Humanin

Two peptides, different evidence streams

View Full Dossiers

Stay Updated on Peptide Comparisons